Skip to main content
Clinical Trials/NCT01644136
NCT01644136
Terminated
Not Applicable

A Pilot Clinical Trial for the Prevention of Postoperative Lymphoceles Using Absorbable Micorporous Polysaccharide Hemosphere Particles During Robotic Assisted Prostatectomy With Lymph Node Dissection

Ohio State University Comprehensive Cancer Center1 site in 1 country99 target enrollmentJuly 14, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphocele
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
99
Locations
1
Primary Endpoint
Incidence of postoperative lymphocele formation
Status
Terminated
Last Updated
7 years ago

Overview

Brief Summary

This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections can become symptomatic in some patients. Arista would be applied to one side of the pelvis after a pelvic lymph node dissection, to see if this decreases the number of postoperative lymph fluid collections seen on a computed tomography (CT) scan after surgery

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether, if applied to the lymph node basins after pelvic lymph node dissection, Arista could potentially reduce the formation of lymphoceles and consequently the need for secondary interventions. OUTLINE: Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis. After completion of study treatment, patients are followed up at 3 months.

Registry
clinicaltrials.gov
Start Date
July 14, 2011
End Date
May 6, 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male patients
  • Patients with prostate cancer who are electing to undergo robotic radical prostatectomy with pelvic lymph node dissection at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center by Dr. Ronney Abaza

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Incidence of postoperative lymphocele formation

Time Frame: 3 months after surgery

The rate of lymphoceles on each side of the pelvis will be compared. Summary statistics will be reported (mean, standard deviation, and range for the continuous variables and frequency and percentages for the categorical variables). In addition, we will determine interrelationships among specific variables using regression and correlation analyses.

Study Sites (1)

Loading locations...

Similar Trials